Infectious disease · Phase II

Top sponsors

• BRIGHT MINDS BIOSCIENCES 27 programs
• United Therapeutics Europe 23 programs
• Chinese Academy of 16 programs
• Takeda 16 programs
• Vir Biotechnology 15 programs
• Vertex Pharmaceuticals (Australia) 12 programs
• Sinovac Research and 11 programs
• GSK Glaxo Smith 10 programs
• ENANTA PHARMACEUTICALS 8 programs
• Arrowhead Pharmaceuticals Ireland 7 programs
• Regeneron UK 7 programs
• Anaxis Pharma 6 programs

1. MMV390048 40mg

   CNS Pharmaceuticals

   Malaria

   phase 2 · small molecule · completed

   1 trial →

2. MP-424 (Telaprevir)

   Vertex Pharmaceuticals (Australia) Pty.

   Hepatitis C

   phase 2 · small molecule · completed

   1 trial →

3. MRx-4DP0004

   4D Molecular Therapeutics

   COVID-19

   phase 2 · small molecule · terminated

   1 trial →

4. Maribavir

   Takeda

   Cytomegalovirus Infection

   phase 2 · small molecule · completed

   1 trial →

5. Mavrilimumab

   Kiniksa Pharmaceuticals International, plc

   COVID-19

   phase 2 · small molecule · completed

   3 trials →

6. Merimepodib

   Vertex Pharmaceuticals (Australia) Pty.

   Hepatitis C

   phase 2 · small molecule · completed

   1 trial →

7. Meropenem-Vaborbactam

   Lacuna Pharma Pty Ltd

   Complicated Urinary Tract Infection (cUTI), Acute Pyelonephritis (AP)

   phase 2 · small molecule · active

   1 trial →

8. Metronidazole

   Teva Pharma GmbH

   Bacterial Vaginosis

   phase 2 · small molecule · completed

   1 trial →

9. Miricorilant

   CORCEPT THERAPEUTICS INC

   Nonalcoholic Steatohepatitis (NASH)

   phase 2 · small molecule · active

   3 trials →

10. Miricorilant (Cohort A)

    CORCEPT THERAPEUTICS INC

    Nonalcoholic Steatohepatitis (NASH)

    phase 2 · small molecule · active

    1 trial →

11. Motavizumab, palivizumab

    MedImmune

    Respiratory Syncytial Virus Infections

    phase 2 · mab · completed

    1 trial →

12. Multimedia WORTH

    BRIGHT MINDS BIOSCIENCES INC.

    HIV

    phase 2 · other · completed

    1 trial →

13. NN9500-4656

    NovoThirteen

    Non-alcoholic steatohepatitis (NASH)

    phase 2 · small molecule · active

    1 trial →

14. NOV-205

    Cellectar Biosciences

    Hepatitis C

    phase 2 · small molecule · completed

    2 trials →

15. NS2

    Aldeyra Therapeutics

    Non-infectious Anterior Uveitis

    phase 2 · small molecule · completed

    1 trial →

16. Namodenoson

    Can-Fite BioPharma

    NASH - Nonalcoholic Steatohepatitis

    phase 2 · small molecule · active

    1 trial →

17. Namodenoson, Matching placebo for namodenoson

    Can-Fite BioPharma

    Non-Alcoholic Steatohepatitis (NASH) with F1-3 fibrosis

    phase 2 · small molecule · active

    1 trial →

18. NestaCell®

    Vera Therapeutics

    COVID-19 Pneumonia

    phase 2 · mab · completed

    1 trial →

19. Norovirus Bivalent Vaccine

    Takeda

    Prevention From Norovirus Infection

    phase 2 · mab · completed

    1 trial →

20. ORMD-0801 QD

    ORAMED PHARMACEUTICALS INC.

    Nonalcoholic Steatohepatitis (NASH)

    phase 2 · small molecule · completed

    1 trial →

21. OT-101

    Oncotelic Therapeutics

    COVID-19

    phase 2 · small molecule · active

    1 trial →

22. OZ439

    CNS Pharmaceuticals

    Malaria

    phase 2 · small molecule · completed

    1 trial →

23. Olorofim

    Biotech Pharmaceutical Co.,

    Invasive Fungal Infections

    phase 2 · small molecule · completed

    1 trial →

24. Opaganib

    RedHill Biopharma

    Coronavirus Infections

    phase 2 · small molecule · completed

    1 trial →

25. Oral Insulin

    ORAMED PHARMACEUTICALS INC.

    Non-Alcoholic Steatohepatitis (NASH)

    phase 2 · mab · completed

    1 trial →

26. Oral Naltrexone

    BRIGHT MINDS BIOSCIENCES INC.

    HIV

    phase 2 · small molecule · completed

    1 trial →

27. PEG-IFNα

    Vir Biotechnology

    Chronic Hepatitis B Virus Infection

    phase 2 · mab · active

    1 trial →

28. PENNVAX-GP

    INOVIO PHARMACEUTICALS, INC.

    HIV-1-infection

    phase 2 · mab · completed

    1 trial →

29. PRO-nCOV-1002

    Sinovac Research and Development Co.,

    COVID-19

    phase 2 · mab · completed

    2 trials →

30. PRO-nCOV-1003

    Sinovac Research and Development Co.,

    COVID-19

    phase 2 · mab · completed

    1 trial →

31. PRO-nCOV-2002

    Sinovac Research and Development Co.,

    COVID-19

    phase 2 · mab · on hold

    1 trial →

32. PRO-nCOV-2004

    Sinovac Research and Development Co.,

    COVID-19

    phase 2 · mab · terminated

    1 trial →

33. PRO-nCOV-2009

    Sinovac Research and Development Co.,

    COVID-19

    phase 2 · mab · completed

    1 trial →

34. PUL-042 Inhalation Solution

    United Therapeutics Europe Ltd

    COVID-19

    phase 2 · small molecule · completed

    2 trials →

35. Part1:Recombinant two-component COVID-19 vaccine (CHO cell)

    Jian Li

    COVID-19

    phase 2 · mab · completed

    1 trial →

36. Phage Therapy

    Adaptive Biotechnologies Corp

    Prosthetic Joint Infection

    phase 2 · mab · terminated

    2 trials →

37. Piclidenoson

    Can-Fite BioPharma

    COVID-19

    phase 2 · small molecule · completed

    1 trial →

38. Placebo

    Spero Therapeutics

    Nontuberculous Mycobacterial Pulmonary Disease (NTM-PD)

    phase 2 · small molecule · completed

    1 trial →

39. Placebo

    Lacuna Pharma Pty Ltd

    Severe Alcohol-Associated Hepatitis

    phase 2 · small molecule · active

    1 trial →

40. Placebo for AZD4144, AZD4144

    AstraZeneca AB

    Sepsis-associated acute kidney injury (AKI)

    phase 2 · small molecule · active

    1 trial →

41. Placebo for AZD5148, AZD5148

    AstraZeneca AB

    Recurrence of Clostridioides difficile Infection

    phase 2 · small molecule · active

    1 trial →

42. Placebo to Match GSK3965193 Tablets

    GlaxoSmithKline

    Hepatitis B

    phase 2 · small molecule · active

    1 trial →

43. PvCS/Montanide ISA-51 VG Vaccine

    BRIGHT MINDS BIOSCIENCES INC.

    Plasmodium Vivax Malaria

    phase 2 · mab · active

    1 trial →

44. RC04T001

    Lacuna Pharma Pty Ltd

    Chronic hepatitis D virus infection

    phase 2 · small molecule · active

    1 trial →

45. REC-3964

    RECURSION PHARMACEUTICALS, INC.

    Recurrent Clostridioides Difficile Infection

    phase 2 · small molecule · terminated

    1 trial →

46. REGN10933+REGN10987 combination therapy

    Regeneron UK Limited

    COVID-19

    phase 2 · small molecule · completed

    2 trials →

47. REGN7041

    Regeneron UK Limited

    Active Noninfectious Uveitis Affecting the Posterior Segment

    phase 2 · small molecule · active

    1 trial →

48. REGN7041

    Lacuna Pharma Pty Ltd

    Noninfectious Uveitis

    phase 2 · small molecule · active

    1 trial →

Frequently asked questions